center-orphan-drug-research contact-us 
pharmaphorum
DECEMBER 21, 2021
However, despite the work still left to be done, there are now a growing number of treatments in the pipeline and 2020 proved to be a remarkable year for orphan drug approvals, with the US FDA approving more orphan designated treatments than non-orphan drugs.
PharmaShots
JANUARY 31, 2023
Shots: Immutable capital demands and high-spending drug development plans are the most common drivers in encouraging fully-fledged private healthcare companies to go public. Founded Year: 2007 No. of Shares: 1.5M Funding Value: $7M Founded Year: 2005 No. of Shares: 1.2M Funding Value: $7.7M Founded Year: 2021 No. of Shares: 1.3M of Shares: 2.1M
Expert insights. Personalized for you.
96 
Let's personalize your content